MandalMed is a privately-held company focused on modulation of glycobiology and innate immunity to develop treatments for organ fibrosis. The initial target is galectin-3, one of a family of carbohydrate binding proteins. The lead product is MM-003, a protein inhibitor of galectin-3, for prevention and reversal of fibrosis after myocardial infarction and in heart failure.
